Michael Amoroso
Chief Commercial Officer
Other
Chairman
CEO
Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2020 | Abeona Therapeutics Inc. (ABEO) | Former President and Chief Executive Officer Fair value of option awards is calculated under ASC 718 as of the grant date using the Black-Scholes option-pricing model and as of the repricing date using a Hull-White I lattice model. Employees are assumed to exercise their options. The determination of the fair value of share-based payment awards made on the date of grant is affected by our Common Stock price as well as assumptions regarding a number of complex and subjective variables. Our assumptions in determining fair value are described in Note 11 of Notes to Consolidated Financial Statements in Part II, Item 8 of the Annual Report. | $219,071 | $1,499,160 |
Executive changes
Earnings-call appearances
-
Abeona Therapeutics Inc. Q2 FY2021 Earnings Call2021-07-28
Abeona Therapeutics Inc. (ABEO)
-
Abeona Therapeutics Inc. Q1 FY2021 Earnings Call2021-05-18
Abeona Therapeutics Inc. (ABEO)
-
Abeona Therapeutics Inc. Q4 FY2020 Earnings Call2021-03-24
Abeona Therapeutics Inc. (ABEO)
-
Abeona Therapeutics Inc. Q3 FY2020 Earnings Call2020-11-09
Abeona Therapeutics Inc. (ABEO)
-
Abeona Therapeutics Inc. Q2 FY2020 Earnings Call2020-08-10
Abeona Therapeutics Inc. (ABEO)